Ponesimod (Ponvory) for Multiple Sclerosis
Date: August 9, 2021
Issue #:
1630Summary:
The FDA has approved ponesimod (Ponvory–
Janssen), a sphingosine 1-phosphate (S1P) receptor
modulator, for treatment of adults with relapsing forms
of multiple sclerosis (MS), including clinically isolated
syndrome (initial neurological episode), relapsing-remitting
disease, and active secondary progressive
MS (SPMS). Ponesimod is the fourth oral S1P receptor
modulator to be approved in the US for once-daily
treatment of relapsing forms of MS; ozanimod(Zeposia) and siponimod(Mayzent) are also approved
for use in adults, and fingolimod(Gilenya) is indicated
for use in patients ≥10 years old.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Source Type: research